Staphylococcus and staphylococcal infections. 5. Toxins of Staphylococcus aureus and toxin related diseases.

1988 ◽  
Vol 50 (5) ◽  
pp. 902-909 ◽  
Author(s):  
JIRO ARATA
Keyword(s):  
Staphylococcus Aureus ◽  
Staphylococcal Infections

scholarly journals Bacteriophage-Derived PeptidaseCHAPKEliminates and Prevents Staphylococcal Biofilms

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Mark Fenton ◽  
Ruth Keary ◽  
Olivia McAuliffe ◽  
R. Paul Ross ◽  
Jim O'Mahony ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Biofilm Formation ◽  
Antibacterial Agents ◽  
Antimicrobial Agents ◽  
Bovine Mastitis ◽  
Economic Losses ◽  
Food Sector ◽  
Staphylococcal Infections ◽  
Prevention And Treatment

New antibacterial agents are urgently needed for the elimination of biofilm-forming bacteria that are highly resistant to traditional antimicrobial agents. Proliferation of such bacteria can lead to significant economic losses in the agri-food sector. This study demonstrates the potential of the bacteriophage-derived peptidase,CHAPK, as a biocidal agent for the rapid disruption of biofilm-forming staphylococci, commonly associated with bovine mastitis. PurifiedCHAPKapplied to biofilms ofStaphylococcus aureusDPC5246 completely eliminated the staphylococcal biofilms within 4 h. In addition,CHAPKwas able to prevent biofilm formation by this strain. TheCHAPKlysin also reducedS. aureusin a skin decolonization model. Our data demonstrates the potential ofCHAPKas a biocidal agent for prevention and treatment of biofilm-associated staphylococcal infections or as a decontaminating agent in the food and healthcare sectors.

scholarly journals Inhibitors of Pantothenate Kinase: Novel Antibiotics for Staphylococcal Infections

2003 ◽  
Vol 47 (6) ◽  
pp. 2051-2055 ◽  
Author(s):  
Anthony E. Choudhry ◽  
Tracy L. Mandichak ◽  
John P. Broskey ◽  
Richard W. Egolf ◽  
Cynthia Kinsland ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Staphylococcus Aureus ◽  
Biosynthetic Pathway ◽  
Coenzyme A ◽  
Low Molecular Weight ◽  
Pantothenate Kinase ◽  
Staphylococcal Infections ◽  
Low Molecular Weight Compounds ◽  
Novel Antibiotics

ABSTRACT Pantothenate kinase (CoaA) catalyzes the first step of the coenzyme A biosynthetic pathway. Here we report the identification of the Staphylococcus aureus coaA gene and characterization of the enzyme. We have also identified a series of low-molecular-weight compounds which are effective inhibitors of S. aureus CoaA.

Alteration in the multiplication of Staphylococcus aureus by Enovid

1969 ◽  
Vol 15 (3) ◽  
pp. 247-252 ◽  
Author(s):  
W. W. Yotis ◽  
J. M. Cummings
Keyword(s):  
Staphylococcus Aureus ◽  
Oral Contraceptive ◽  
Chemical Reactions ◽  
Adult Female ◽  
Mortality Rates ◽  
Female Mice ◽  
Staphylococcal Infections ◽  
Bacteriostatic Action ◽  
Therapeutic Doses

The widespread use of oral contraceptive drugs stimulated an assessment of one such compound for any effects on staphylococci. In vitro turbidimetric studies indicated that norethynodrel in therapeutic doses had a bacteriostatic action on the growth of staphylococci. When adult female mice received 2.5 μg norethynodrel and 1.2 μg mestranol intraperitoneally on each of 3 days before intravenous challenge with virulent staphylococci, the spleens and kidneys of the norethynodrel–mestranol (Enovid) treated mice contained one-half to one-third lower viable staphylococcal counts than those obtained from the same organs of the control mice. Furthermore, during the first several days after infection the Enovid-treated mice showed reduced mortality rates in comparison to those observed in the control mice. Thus, Enovid may affect the development of staphylococcal infections or chemical reactions governing the growth of staphylococci.

scholarly journals Incidence of clindamycin resistance in clinical isolates of Staphylococcus aureus

2011 ◽  
Vol 5 (04) ◽  
pp. 316-317 ◽  
Author(s):  
Debmita Debdas ◽  
Sangeeta Joshi
Keyword(s):  
Staphylococcus Aureus ◽  
Empiric Therapy ◽  
Clinical Isolates ◽  
Inducible Clindamycin Resistance ◽  
Clinical Specimens ◽  
Staphylococcal Infections ◽  
Resistance Patterns

Clindamycin is used in Staphylococcal infections and resistance patterns to Clindamycin vary between institutions. Inducible Clindamycin resistance is detected by the CLSI recommended D-test. This study was done to estimate the incidence of constitutive and inducible Clindamycin resistance in our hospital. Three hundred and seventy nine S.aureus isolates from clinical specimens collected over 6 months were tested for Clindamycin resistance using the D-test. Fourteen percent were Clindamycin resistant and among them 43% showed the inducible phenotype. Clindamycin resistance was higher among MRSA isolates (p < 0.001). It was concluded that Clindamycin should not be used empirically in serious Staphylococcal infections and that such studies are necessary to guide empiric therapy.

scholarly journals Effect of Ciprofloxacin on the Growth and Biofilm Formation Ability of Staphylococcus aureus

2021 ◽  
pp. 44-59
Author(s):  
N. Queenette, Obinaju ◽  
C. Chukwunonyerem, Ogwunga ◽  
O. Sylvia, Anyadoh-Nwadike ◽  
U. Emmanuel, Nwakwasi
Keyword(s):  
Staphylococcus Aureus ◽  
Defense Mechanism ◽  
Bacterial Flora ◽  
Protein A ◽  
Inhibitory Effect ◽  
Phenotypic Characterization ◽  
Upper Respiratory Tract ◽  
Staphylococcal Infections ◽  
Superficial Skin ◽  
Time Kill

Staphylococcus aureus is part of the normal bacterial flora of the skin, intestine and upper respiratory tract of both humans and animals and has the potential of causing staphylococcal infections if there is a breach in the hosts’ defense mechanism. These infections could range from mild superficial skin infections to more severe and even fatally invasive diseases such as sepsis and toxic shock syndrome. The infectivity of S. aureus is attributed to its ability to withstand extreme conditions and its possession of various virulence factors. The aim of this project was to study the effect of ciprofloxacin on the growth and biofilm forming ability of CM10 strain of Staphylococcus aureus using time kill study, resazurin and live/dead staining of biofilms and Real-time polymerase chain reaction. The identity of the given CM10 strain was confirmed when the result of the API-Staph was in total accordance with the results obtained from the colony morphology and phenotypic characterization tests (Coagulase/protein A, Gram, and Catalase tests). CM10 strain of S. aureus was not susceptible to 0.25mg/L of ciprofloxacin used for the time kill experiment but was susceptible to a minimum inhibitory concentration of 0.5mg/L. The difference between the ciprofloxacin treated biofilms of CM10 strain and the untreated biofilms was significant (P<0.05) showing that ciprofloxacin has an adverse effect on the cells in the biofilm. The results of this study provide an insight on the growth as well as the biofilm forming ability of CM10 strain of Staphylococcus aureus. Ciprofloxacin has been shown to be an effective antibacterial against this strain of S. aureus by its inhibitory effect on the growth as well as biofilm forming ability of this strain of S. aureus.  This information would assist in developing novel anti-biofilm therapies to help in the management of biofilm mediated infections thereby reducing the morbidity and mortality rate of staphylococcal infections.

Sign in / Sign up

Export Citation Format

Share Document